Categories: News

Ipsen – Half year statement – 2023 06 30

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

Paris (France), July 10, 2023 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of June 30, 2023, the following resources were included to the dedicated liquidity account:

  • 17,348 shares
  • €3,350,842.85

It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account:

  • 12,751 shares
  • €3,137,934.80

Between January 1st, 2023 and June 30, 2023 have been executed:

  • 3,153 purchase transactions
  • 2,820 sell transactions

Under the same period, the volumes traded represented:

  • 360,894 shares and €38,313,096.35 to the purchase
  • 367,615 shares and €39,180,843.15 to the sell

Attachment

Staff

Recent Posts

Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics

GENEVA, SWITZERLAND / ACCESS Newswire / December 15, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX)…

3 hours ago

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery BRISBANE, Australia…

21 hours ago

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading…

21 hours ago

President Trump’s Cannabis Decision Is Coming – And Why MMJ International Holdings Wins Either Way

12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…

2 days ago

Accelerating Patient Recruitment and Research Excellence: TrialWire® Supports Endpoints Clinical Trials Day NYC 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…

2 days ago